SILO (Silo Pharma, Inc.) חוב לטווח קצר להון

Silo Pharma, Inc. (SILO) is vulnerable to global political instability affecting component procurement and patent protection. Market fluctuations in the share price reflect the current indicator 0.00. The business relies on the development of innovative treatments for Alzheimer's and PTSD. The company is currently focusing on R&D for the targeted delivery of psychedelics, planning to bring new therapeutic solutions to market by 2026.

To assess the financial stability of Silo Pharma, Inc. (SILO), the ratio of short-term liabilities to equity is used, measuring the proportion of debts maturing within one year in the financing structure. Given the strict FDA oversight and costly R&D developments, this chart of short-term liabilities to equity helps identify liquidity risks that are critical for maintaining patent protection and clinical trials.